AstraZeneca and Galderma Pharma have entered into a five-year R&D collaboration to develop new treatments for dermatological conditions.

The partnership will focus on dermatological conditions such as psoriasis, acne and atopic dermatitis.

Under the terms of the agreement, Galderma will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop dermatological indications.

The parties have already identified the initial targets for collaboration from AstraZeneca’s oncology, inflammation and central nervous system portfolios.

The targets will be evaluated based on translational science and pre-clinical testing to determine the ones that will progress in the collaboration.

The financial terms of the agreement were not disclosed.